The clinical and cost effectiveness of testing for cytochrome P450 polymorphisms in patients treated with antipsychotics: a systematic review and economic evaluation

Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, de Warren-Penny P, Dickson R
Record ID 32010000103
Authors' recommendations: Review found that cytochrome P450 pharmacogenetic testing in adults entering antipsychotic treatment for schizophrenia may show promise in terms of predicting adverse drug reactions such as tardive dyskinesia but further evidence for clinical effectiveness and cost-effectiveness is required.
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Adult
  • Cost-Benefit Analysis
  • Pharmacogenetics
  • Polymorphism, Genetic
  • Antipsychotic Agents
  • Cytochrome P-450 Enzyme System
  • Genetic Testing
  • Schizophrenia
  • State Medicine
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
Contact Email:
Copyright: 2010 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.